Drilldown: Medicines

Famotidine (1) · Tamsulosin (1)

Flomax (1) · Pepcid, Pepcid AC, Pepcid Complete (1)

[[:Category:Alpha-1_blockers|Alpha-1A adrenergic blocker]] (1) · [[:Category:Antisecretory_agents|Gastric acid suppressant]] (1) · [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] (1) · [[:Category:H2_receptor_antagonists|Histamine H2 receptor antagonist]] (1)

None (1) · '"`UNIQ--vote-00000255-QINU`"' Less potent and shorter-acting than PPIs but with faster on-effect; suitable for on-demand acid suppression. Largely renally cleared; dose-adjust in renal impairment to avoid CNS effects (confusion in elderly)'"`UNIQ--ref-00000256-QINU`"'. (1)

'"`UNIQ--vote-000001BA-QINU`"', '"`UNIQ--vote-000001BB-QINU`"' (1) · '"`UNIQ--vote-00000257-QINU`"', '"`UNIQ--vote-00000258-QINU`"', '"`UNIQ--vote-00000259-QINU`"', '"`UNIQ--vote-0000025A-QINU`"' (1)

None · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose · '''5 mg PO at bedtime for women, 5-10 mg for men''' (per FDA's 2013 sex-specific dose reduction for women due to slower clearance). Ambien CR 6.25 mg women / 6.25-12.5 mg men. Intermezzo SL 1.75 mg women / 3.5 mg men · 0.25 mg · 0.4 mg PO daily (general prevention); 0.8-1 mg/d in pregnancy; 4 mg/d for women with prior NTD-affected pregnancy; 1 mg/d during methotrexate therapy · 0.4 mg PO once daily, 30 minutes after the same meal each day · 0.5 mg PO once daily · 0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg · 0.5-2 mg/kg/d divided or single morning dose for acute conditions; lowest effective dose for chronic conditions, with planned taper · 0.5-3 mg PO 30-60 minutes before bedtime. Some patients respond to micro-doses (0.3 mg) without additional benefit at higher doses. For circadian phase shifting, timing relative to dim-light melatonin onset matters more than absolute dose · 0.5–1 oz (10–30 g) ground for psychoactive effect; far smaller for culinary use · 0.75 mg SC weekly'"`UNIQ--ref-00000053-QINU`"' · 1 capsule (20/10 mg dextromethorphan/quinidine) PO once daily × 7 days, then 1 capsule BID · 1 drop in affected eye(s) TID (monotherapy); BID with timolol (Cosopt) · 1 drop in the affected eye(s) once daily in the evening · 1 drop in the affected eye(s) once daily in the evening (Lumigan); Latisse applied to upper lash line at bedtime · 1 g PO QID on an empty stomach (1 hour before meals and at bedtime); 1 g BID for maintenance · 1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) · 1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg · 1 mg PO once daily

Other values:

Search

0.4 mg capsules (1) · 10 mg, 20 mg, 40 mg tablets; chewables; 40 mg/5 mL oral suspension; 10 mg/mL IV (1)

0.8 mg/d (rarely needed) (1) · 160 mg/d (Zollinger-Ellison); 80 mg/d for routine indications (1)

IV (1) · Oral (2)

1 hour PO; minutes IV (1) · Symptom improvement within 1 week; peak effect at 4-6 weeks (1)

24 hours (1) · 6-12 hours (1)

2.5-3.5 hours; longer in renal impairment'"`UNIQ--ref-0000025B-QINU`"' (1) · 9-15 hours'"`UNIQ--ref-000001BC-QINU`"' (1)

40-45% (oral; not significantly affected by food)'"`UNIQ--ref-0000025C-QINU`"' (1) · >90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)'"`UNIQ--ref-000001BD-QINU`"' (1)

Generally considered safe; widely used. Cleared in lactation at low levels.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not applicable (male indication); historical Category B if used in unrelated female cases.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

OTC (10-20 mg) and [[USLegal:Prescription only|Rx-only]] (higher doses) in US (1) · [[USLegal:Prescription only|Rx-only]] in US (1)